Wen Wang

Prof. Wen Wang

First Hospital of China Medical University, Shenyang, Liaoning, China
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
WWWen Wang
Wen Wang
HLHui Lu
Hui Lu
XLXu Lu
Xu Lu
DWDonglei Wang
Donglei Wang
ZWZhaohan Wang
Zhaohan Wang
PLPei Liu
Pei Liu
Ammonia and tumor necrosis factor-alpha (TNF-α) play important roles in the mechanisms of hepatic encephalopathy (HE). Rhesus glycoprotein C (Rhcg) is important for ammonia transport especially in the kidney. The aim of the present study was to investigate the role of Rhcg in the brain in acute liver failure (ALF) and the effect of TNF-α on Rhcg expression. ALF mouse models were generated by treatment with d-galactosamine (D-GalN) and lipopolysaccharide (LPS), or D-GalN and TNF-α. ALF induction was blocked by pretreatment with anti-TNF-α IgG. The levels of serum TNF-α were determined by ELISA. Blood ammonia and brain ammonia concentrations were detected using an ammonia assay kit. The expression and distribution of Rhcg in the brain tissues of ALF mice were examined by western blotting, real-time PCR, immunohistochemical, and immunofluorescence analyses. Serum TNF-α levels were increased in the LPS/D-GalN group. Blood and brain ammonia were increased in the LPS/D-GalN- and TNF-α/D-GalN-induced ALF groups. Rhcg mRNA and protein levels were elevated in both ALF groups, consistent with the increase in blood and brain ammonia. Rhcg was mainly expressed in vascular endothelial cells and astrocytes. Pretreatment with anti-TNF-α IgG antibody downregulated Rhcg in brain tissues in the LPS/D-GalN group, prevented the occurrence of ALF, and reduced blood and brain ammonia levels in the LPS/D-GalN group. TNF-α promoted the transport of ammonia from the blood to brain tissues and exacerbated the toxic effects of ammonia by upregulating Rhcg.

7 January 2020 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
WWWen Wang
Wen Wang
XLXu Lu
Xu Lu
CLChengbo Li
Chengbo Li
MRMyong Jun Ri
Myong Jun Ri
WCWei Cui
Wei Cui
Background: We report a rare case of chronic brucellosis accompanied with myelodysplastic syndrome and neutrophilic dermatosis, which to the best of our knowledge, has never been reported. Case presentation: A young man was admitted to our hospital complaining of recurrent fever, arthritis, rashes and anemia. He had been diagnosed with brucellosis 6 years prior and treated with multiple courses of antibiotics. He was diagnosed with myelodysplastic syndrome and neutrophilic dermatosis following bone marrow puncture and skin biopsy. After anti-brucellosis treatment and glucocorticoid therapy, the symptoms improved. Conclusions: Clinicians should consider noninfectious diseases when a patient who has been diagnosed with an infectious disease exhibits changing symptoms.

8 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLChengbo Li
Chengbo Li
YZYing Zhou
Ying Zhou
YWYu Wang
Yu Wang
SLSheng Liu
Sheng Liu
WWWen Wang
Wen Wang
YWYing Wen
Ying Wen
Background: In this study, we surveyed the prevalence of hepatitis B virus (HBV) surface antigen (HBsAg) and hepatitis C virus (HCV) antibody (anti-HCV) among inpatients with human immunodeficiency virus (HIV) infection and analyzed the correlated factors. Methods: We conducted a retrospective data collection of the HIV-infected inpatients in our hospital from January 2010 to December 2020. We utilized multivariate logistic regression to identify the correlated factors. Results: The proportion of patients screened for HBsAg was 81.8%, which increased from 66.7% in 2010 to 85.7% in 2020. The proportion of patients with anti-HCV screening was 73.9%, which increased from 58.3% in 2010 to 86.7% in 2020. The prevalence of HBsAg positivity was 10.9%, which decreased from 15.0% in the period of 2010–2015 to 9.0% during 2016–2020. Positive anti-HCV was identified in 4.1% of cases. Compared to 4.8% in the period of 2010–2015, there was a similar prevalence of anti-HCV at 3.1% during 2016–2020. Among the HBsAg-positive cases, HBV deoxyribonucleic acid was screened in 70.8% of cases. Among the anti-HCV positive cases, HCV ribonucleic acid (RNA) was screened in 90% of cases. Albumin < 30 g/L, thrombocytopenia and aspartate aminotransferase (AST) > 40 U/L were associated with HBsAg positivity. AST > 40 U/L and higher CD4-positive T lymphocyte counts were associated with HIV/HCV coinfection. Conclusions: The routine screening for both HBV and HCV among HIV-positive inpatients has been greatly improved in the past decade. However, screening for the complete HBV serological markers in HIV-positive inpatients and HCV genotyping among HCV RNA-positive cases leaves much to be desired. A concerted effort should be made to improve HBV vaccine compliance in the HIV-positive population and provide direct-acting antiviral therapies to HCV RNA-positive patients.

29 December 2025 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
WWWen Wang
Wen Wang
JYJun Yang
Jun Yang
ZWZiqiu Wang
Ziqiu Wang
YWYing Wen
Ying Wen
The management of advanced HIV can be complicated by immune reconstitution inflammatory syndrome (IRIS) and cerebrospinal fluid (CSF) viral escape. We report a novel case of symptomatic CSF escape driven by a rare bictegravir resistance mutation, emerging after a severe unmasking IRIS event. A 61-year-old male patient with advanced HIV (clusters of differentiations 4+ T-cell count 31 cells/μl) initiated antiretroviral therapy with bictegravir/emtricitabine/tenofovir alafenamide. A total of 1 week later, he developed varicella-zoster virus-associated acute retinal necrosis, consistent with IRIS. Despite successful ocular treatment, he later developed progressive neurocognitive decline. Investigations confirmed CSF HIV escape (CSF HIV-RNA 7100 copies/ml; plasma 583 copies/ml). Resistance testing revealed an M184V mutation and, critically, an R263K mutation conferring resistance to integrase strand transfer inhibitors. His regimen was switched to zidovudine/lamivudine/lopinavir/ritonavir, leading to dramatic clinical improvement, undetectable CSF HIV-RNA, and reduced leptomeningeal enhancement on magnetic resonance imaging. To the best of our knowledge, this is the first reported case of symptomatic CSF escape with documented bictegravir resistance in a treatment-naïve, adherent patient. It demonstrates that sanctuary site-specific resistance can develop against key first-line regimens and highlights the need for a revised therapeutic strategy. CSF viral load quantification and resistance genotyping are essential in such scenarios to guide effective, personalized therapy.